HanX Biopharmaceuticals Signs a License Agreement with Onconova to Develop and Commercialize Rigosertib in Greater China

 HanX Biopharmaceuticals Signs a License Agreement with Onconova to Develop and Commercialize Rigosertib in Greater China

HanX Biopharmaceuticals Signs a License Agreement with Onconova to Develop and Commercialize Rigosertib in Greater China

Shots:

  • Onconova to receive e $6M upfront including $2M cash, $2M shares & $2M as escrow funding with $45.5M regulatory, development & commercial milestones and royalties on sales. HanX to get an exclusive license for development & commercialization & non-exclusive license to manufacture rigosertib in Greater China
  • The focus of the collaboration is to join Onconova’s INSPIRE study and to initiate a study to evaluate the combination of oral rigosertib with azacitidine & POC study for the combination of rigosertib with a PD-1 inhibitor in NSCLC + Ras mutations
  • Rigosertib is a targeted anti-cancer therapy, currently being evaluated in P-III INSPIRE trials in patients with HR-MDS with its expected completion in H2’19 and has received ODD for MDS in the US & Europe. Additionally, Onconova collaborated with SymBio & Pint Pharma for rigosertib in Japan, Korea & Latin America respectively

Click here to read full press release/ article | Ref: Onconova | Image:Contract Pharma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post